Agenus (NASDAQ:AGEN) Stock Rating Lowered by Wall Street Zen

Agenus (NASDAQ:AGEN) was downgraded by research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Saturday.

Other equities research analysts also recently issued reports about the stock. Weiss Ratings reiterated a “sell (d)” rating on shares of Agenus in a report on Tuesday, June 16th. Zacks Research downgraded shares of Agenus from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 11th. Finally, HC Wainwright raised their target price on shares of Agenus from $23.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Agenus has a consensus rating of “Hold” and a consensus price target of $30.00.

Agenus Price Performance

AGEN opened at $5.01 on Friday. The firm has a market cap of $208.62 million, a P/E ratio of 3.15 and a beta of 1.55. The business’s fifty day simple moving average is $3.44 and its 200 day simple moving average is $3.49. Agenus has a 52 week low of $2.71 and a 52 week high of $8.70.

Agenus (NASDAQ:AGEN) last announced its earnings results on Monday, May 11th. The biotechnology company reported $1.02 earnings per share for the quarter, missing the consensus estimate of $2.10 by ($1.08). The firm had revenue of $33.74 million during the quarter, compared to analyst estimates of $129.50 million. Agenus had a net margin of 50.49% and a negative return on equity of 31.66%. As a group, equities analysts expect that Agenus will post 0.83 EPS for the current fiscal year.

Hedge Funds Weigh In On Agenus

Several large investors have recently added to or reduced their stakes in AGEN. EP Wealth Advisors LLC purchased a new stake in Agenus in the 4th quarter valued at about $31,000. R Squared Ltd acquired a new position in shares of Agenus during the 4th quarter valued at about $41,000. Redwood Family Wealth LLC purchased a new position in shares of Agenus during the 4th quarter worth about $44,000. Quadrature Capital Ltd purchased a new position in shares of Agenus during the 4th quarter worth about $54,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Agenus in the third quarter worth approximately $54,000. 61.46% of the stock is currently owned by hedge funds and other institutional investors.

Agenus Company Profile

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.